Action Appili Therapeutics - APLI

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,04

Prix Achat

0,035

Prix Vente

0,04

Volume échangé

37 000

0,035 Fourchette du Jour 0,04

0,025 Plage de 52 semaines 0,06

Cap du marché

4,851M

Clôture Veille

0,035

Ouverture

0,035

Dernière Transaction

2000

0.04

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

56 025

Actions en circulation

121 266 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-1,28

Bénéfice par action (BPA)

-0,03

Chiffre d'affairess

6,69M

Bénéfice net

-3,78M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.appilitherapeutics.com

Siège social

Halifax, Nova Scotia, Can

Fondé

Appili Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la Toronto Stock Exchange avec le ticker APLI. Le dernier cours de clôture d'Appili Therapeutics était de $0,04. Au cours de la dernière année, les actions de Appili Therapeutics ont été négociées dans une fourchette de prix de $ 0,025 à $ 0,06.

Appili Therapeutics compte actuellement 121 266 000 actions en circulation. La capitalisation boursière d'Appili Therapeutics est de $4,24 million. Appili Therapeutics a un ratio cours/bénéfice (ratio PE) de -1.28.

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key...

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025...

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s...

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc...

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova...

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.01	33.3333333333	0.03	0.045	0.03	150343	0.03324538	CS
4	0.005	14.2857142857	0.035	0.045	0.03	56863	0.03325591	CS
12	0.01	33.3333333333	0.03	0.045	0.03	56025	0.0339543	CS
26	0	0	0.04	0.045	0.025	81453	0.03339223	CS
52	0.015	60	0.025	0.06	0.025	120421	0.03773535	CS
156	-0.08	-66.6666666667	0.12	0.17	0.025	148601	0.05466796	CS
260	-1.09	-96.4601769912	1.13	1.6	0.025	159870	0.26789286	CS

APLI - Frequently Asked Questions (FAQ)

What is the current Appili Therapeutics share price?

The current share price of Appili Therapeutics is $ 0,04

How many Appili Therapeutics shares are in issue?

Appili Therapeutics has 121 266 000 shares in issue

What is the market cap of Appili Therapeutics?

The market capitalisation of Appili Therapeutics is CAD 4,24M

What is the 1 year trading range for Appili Therapeutics share price?

Appili Therapeutics has traded in the range of $ 0,025 to $ 0,06 during the past year

What is the PE ratio of Appili Therapeutics?

The price to earnings ratio of Appili Therapeutics is -1,28

What is the cash to sales ratio of Appili Therapeutics?

The cash to sales ratio of Appili Therapeutics is 0,73

What is the reporting currency for Appili Therapeutics?

Appili Therapeutics reports financial results in CAD

What is the latest annual turnover for Appili Therapeutics?

The latest annual turnover of Appili Therapeutics is CAD 6,69M

What is the latest annual profit for Appili Therapeutics?

The latest annual profit of Appili Therapeutics is CAD -3,78M

What is the registered address of Appili Therapeutics?

The registered address for Appili Therapeutics is 21-1344 SUMMER STREET, HALIFAX, NOVA SCOTIA, B3H 0A8

What is the Appili Therapeutics website address?

The website address for Appili Therapeutics is www.appilitherapeutics.com

Which industry sector does Appili Therapeutics operate in?

Appili Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
BNGBengal Energy Ltd	$ 0,01 (100,00%)	90k
SMCSulliden Mining Capital Inc	$ 0,015 (50,00%)	1 000
APSAptose Biosciences Inc	$ 0,275 (30,95%)	261,48k
RTGRTG Mining Inc	$ 0,03 (20,00%)	3,96k
DRR.UDream Residential Real Estate Investment Trust	US$ 7,82 (15,85%)	62,76k
TFIITFI International Inc	$ 143,76 (-20,80%)	29,99k
ELEFSilver Elephant Mining Corp	$ 0,24 (-14,29%)	102,81k
DIAMStar Diamond Corporation	$ 0,035 (-12,50%)	103,23k
WLLWWillow Biosciences Inc	$ 0,035 (-12,50%)	180,69k
NCFNorthcliff Resources Ltd	$ 0,035 (-12,50%)	69k
CNQCanadian Natural Resources Ltd	$ 43,49 (0,44%)	16,65M
CVECenovus Energy Inc	$ 21,64 (-2,83%)	11,3M
MFCManulife Financial Corporation	$ 45,13 (6,64%)	9,09M
BTOB2Gold Corp	$ 3,98 (5,29%)	9,07M
SUSuncor Energy Inc	$ 56,93 (0,33%)	6,44M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Appili Therapeutics Inc (APLI)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Appili Therapeutics Inc

APLI Dernières nouvelles

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

APLI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Appili Therapeutics Inc (APLI) Cours

Appili Therapeutics Inc (APLI)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Appili Therapeutics Inc

APLI Dernières nouvelles

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

APLI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités